Not Yet RecruitingNot Applicable

PD-L1 Targeting Peptide Probe for PET Imaging of Solid Tumor

40 participantsStarted 2026-02

Plain-language summary

The objective of this study is to construct a noninvasive approach using radiolabbled peptide 68Ga-cPP-BCH PET/CT to detect the PD-L1 expression of tumor lesion in patients with lung cancer, melanoma and other solid tumor to identify patients benefiting from anti-PD-(L)1 treatment.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Aged 18-75, male and female, with ECOG score of 0 or 1;
✓. Subjects with lung cancer, melanoma, or other solid tumors scheduled for immunotherapy or combined immunotherapy;
✓. underwent PD-L1 IHC examination before therapy;
✓. The expected survival was more than 26 weeks;
✓. Blood routine test, liver and kidney function meet the following standards: blood routine: WBC \>= 4.0 x 10\^9/L or neutrophil \>= 1.5 x 10\^9/:, PLT \>= 100 x 10\^9 / L, Hb \>= 90g / L; Pt or APTT \<= 1.5 upper limit of normal value; liver and kidney function: total bilirubin \<= 1.5 x ULT (upper limit of normal value), ALT / AST \<= 2.5 upper limit of normal value or \<= 5 x ULT (subject with liver metastasis), ALP \<= 2.5 upper limit of normal value (if bone metastasis or liver metastasis exists, ALP \<= 4.5 upper limit of normal value); BUN \<= 1.5 x ULT, SCR \<= 1.5 x ULT;
✓. According to RECIST1.1, there was at least one measurable target lesion;
✓. Understand and sign informed consent voluntarily with good compliance.

Exclusion criteria

✕. The function of liver and kidney was seriously abnormal;
✕. Preparation for pregnant, pregnant and lactating women;
✕. Inability to lie flat for half an hour;
✕. Suffering from claustrophobia or other mental disorders;
✕. Other researchers considered it unsuitable to participate in the trial.

What they're measuring

MPR

Timeframe: 3-6 months

Trial details

NCT IDNCT07442292

SponsorPeking University Cancer Hospital & Institute

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-12

Contact for this trial

Hua Zhu, Professor

+86-010-88196495 zhuhuabch@pku.edu.cn

View on ClinicalTrials.gov More Lung Cancer (NSCLC) trials